Literature DB >> 24687804

No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis.

Tessel F Runia1, Marjan van Meurs2, Kazem Nasserinejad3, Rogier Q Hintzen4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24687804     DOI： 10.1177/1352458514528765

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  5 in total

Review 1.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

2.  Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Authors:  Nausicaa Clemente; Cristoforo Comi; Davide Raineri; Giuseppe Cappellano; Domizia Vecchio; Elisabetta Orilieri; Casimiro L Gigliotti; Elena Boggio; Chiara Dianzani; Melissa Sorosina; Filippo Martinelli-Boneschi; Marzia Caldano; Antonio Bertolotto; Luca Ambrogio; Daniele Sblattero; Tiziana Cena; Maurizio Leone; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Front Immunol       Date:  2017-03-23       Impact factor: 7.561

Review 3.  Biomarkers of therapeutic response in multiple sclerosis: current status.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

4.  Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.

Authors:  Elena Bonechi; Alessandra Aldinucci; Benedetta Mazzanti; Massimo di Gioia; Anna Maria Repice; Cinzia Manuelli; Riccardo Saccardi; Luca Massacesi; Clara Ballerini
Journal:  Ann Clin Transl Neurol       Date:  2014-08-29       Impact factor: 4.511

Review 5.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.